Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis

Trial Profile

Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2017

At a glance

  • Drugs QR 010 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; First in man
  • Sponsors ProQR Therapeutics
  • Most Recent Events

    • 25 Sep 2017 According to a ProQR Therapeutics media release, data from the trial will be presented at the North American CF Conference (NACFC) on November 2-4, 2017.
    • 25 Sep 2017 Topline results from phase Ib part of the trial published in a ProQR Therapeutics media release.
    • 29 Aug 2017 According to a ProQR Therapeutics media release, dosing of cystic fibrosis patients in the phase 1b portion has been completed and top-line data are scheduled to be announced on Monday, September 25, 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top